Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs
Company is led by cancer immunotherapy and protein engineering pioneer Daniel S. Chen, M.D., Ph.D. SYNTHBODY™ platform increases targeted payload delivery ≥10x compared to current ADCs; expects to enter the clinic in 2026 SAN FRANCISCO–(BUSINESS WIRE)–Synthetic Design…